STOCK TITAN

Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Kestra Medical Technologies (KMTS) announced publication of ACE-PAS results, showing its ASSURE wearable defibrillator met both primary safety and effectiveness endpoints.

The prospective post-approval study enrolled 21,612 patients across 35 U.S. states. ASSURE converted all 303 analyzable ventricular tachycardia or ventricular fibrillation (VT/VF) shock events with one or more shocks. The inappropriate-shock rate was 0.0065 per patient-month, beating the prespecified safety goal. Median daily wear was 23.1 hours; 94% of patients had no false-positive shock alarms.

VT/VF occurred in 2.6% of patients, with events continuing beyond the first month. Results appeared in the Journal of Cardiovascular Electrophysiology. Kestra projects that an enhanced detection algorithm introduced in April 2026 will reduce the inappropriate-shock rate by nearly 70%, to 0.0020 per patient-month.

Loading...
Loading translation...
5 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointASSURE achieved 100% all-shock conversion across 303 analyzable VT/VF shock events, meeting the primary effectiveness endpoint.
  • Major pointThe inappropriate-shock rate of 0.0065 per patient-month beat the prespecified safety goal, meeting the primary safety endpoint.
  • Minor point94% of patients experienced no false-positive shock alarms.
  • Minor pointMedian daily wear reached 23.1 hours; 30% continued beyond 90 days while maintaining that median.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Kestra projects its enhanced algorithm will reduce inappropriate shocks by nearly 70%, to 0.0020 per patient-month.

Negative

  • None.

Key Figures

Patients enrolled: 21,612 patients All-shock conversion success: 100% Inappropriate-shock rate: 0.0065 per patient-month +5 more
Patients enrolled
21,612 patients
ACE-PAS prospective real-world study
All-shock conversion success
100%
303 analyzable VT/VF shock events; primary effectiveness endpoint
Inappropriate-shock rate
0.0065 per patient-month
Outperformed the prespecified safety performance goal
Patients with no false-positive shock alarms
94%
ACE-PAS
Median daily wear
23.1 hours
ACE-PAS patients
Patients with at least one VT/VF event
2.6%
Shocked or unshocked events
Estimated 90-day VT/VF risk
3.2%, 2.8%, and 2.5%
Following myocardial infarction, in ischemic cardiomyopathy, and in nonischemic cardiomyopathy, respectively; patients with LVEF ≤35% meeting primary-prevention criteria
Projected inappropriate-shock-rate decrease
Nearly 70%, from 0.0065 to 0.0020 per patient-month
With the enhanced detection algorithm

Key Terms

wearable cardioverter defibrillators, lvef, ventricular tachycardia, ventricular fibrillation
4 terms
wearable cardioverter defibrillators medical
"study of wearable cardioverter defibrillators (WCD) to date"
A wearable cardioverter defibrillator is a lightweight, vest-like medical device worn by a patient that continuously monitors heart rhythm and automatically delivers an electric shock if it detects a life-threatening arrhythmia. Think of it as a portable emergency defibrillator that protects a person temporarily while doctors assess long-term treatment. Investors track these devices because their sales, clinical evidence, regulatory approvals and insurance reimbursement affect manufacturers’ revenue, adoption rates and health-care spending.
lvef medical
"Among patients with LVEF ≤35%"
Left ventricular ejection fraction (LVEF) is a percentage that measures how much blood the heart’s main pumping chamber pushes out with each beat, like the share of water a pump empties from a bucket each cycle. Investors watch LVEF because it’s a key medical yardstick used to diagnose and track heart function, shaping demand for drugs, devices, clinical trials, insurance costs and the financial outlook of healthcare-related businesses.
ventricular tachycardia medical
"early risk of ventricular tachycardia and ventricular fibrillation"
A fast, abnormal heartbeat that starts in the heart’s lower chambers and can sharply reduce blood flow, potentially causing dizziness, fainting or, in severe cases, sudden collapse; picture an engine running so fast it loses power. For investors, ventricular tachycardia matters because demand for drugs, devices, diagnostic tests and emergency care tied to this condition affects clinical trial results, regulatory approvals, revenue prospects and legal or safety risks for healthcare companies.
ventricular fibrillation medical
"ventricular tachycardia and ventricular fibrillation (VT/VF)"
A life-threatening heart condition in which the heart’s electrical signals become chaotic and the lower chambers quiver instead of pumping blood effectively, like a car engine misfiring so it can’t move the vehicle. It matters to investors because it drives demand for emergency care, medical devices, drugs and diagnostics, affects clinical trial outcomes and regulatory decisions, and can influence healthcare costs, insurer liabilities and the valuation of companies tied to cardiac treatment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

KIRKLAND, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced publication of primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS) in the Journal of Cardiovascular Electrophysiology. The largest prospective real-world study of wearable cardioverter defibrillators (WCD) to date, ACE-PAS enrolled 21,612 patients across 35 U.S. states and met both primary safety and effectiveness endpoints. The study demonstrated 100% all-shock conversion success and sustained daily wear, while documenting ventricular arrhythmias early and continuously over subsequent months. The findings strengthen the clinical case for the ASSURE system across WCD indications and underscore the importance of protecting patients throughout periods of elevated arrhythmic risk.

“Advances in medical therapy have improved cardiac recovery after a myocardial infarction or a new heart failure diagnosis, but the recovery period can leave patients vulnerable to life-threatening ventricular arrhythmias,” said Jeanne E. Poole, MD, Professor of Medicine at the University of Washington and Principal Investigator. “ACE-PAS confirmed the early risk of ventricular tachycardia and ventricular fibrillation (VT/VF) and demonstrates why WCD protection matters: it provides an opportunity to prevent sudden cardiac death while giving patients time to recover.”

The publication provides a full report of findings first presented as late-breaking science at the American Heart Association Scientific Sessions 2025, along with additional analyses of arrhythmic risk. Key findings include:

  • 100% all-shock conversion  
    • ASSURE WCD successfully converted all 303 analyzable VT/VF shock events with one or more shocks, meeting the primary effectiveness endpoint. 
  • Primary safety endpoint achieved 
    • The inappropriate-shock rate was 0.0065 per patient-month, outperforming the prespecified safety performance goal.
  • 94% of patients experienced no false-positive shock alarms
    • The low alarm burden supports a better patient experience and helps enable the sustained wear needed for continuous protection.
  • 23.1 hours of median daily wear—even beyond 90 days
    • Patients wore ASSURE for a median of 23.1 hours per day.
    • 30% continued use beyond 90 days while maintaining the same median daily wear time, highlighting ASSURE’s practicality in real-world, long-term care.
  • VT/VF risk persisted beyond the first month
    • 2.6% of patients experienced at least one shocked or unshocked VT/VF event. While 55% of episodes occurred during the first month, events continued in subsequent months—reinforcing the need for protection throughout the prescription period.
  • Meaningful arrhythmic risk extended across major etiologies
    • Among patients with LVEF ≤35% who met primary-prevention criteria for sudden cardiac death, the estimated risk of experiencing VT/VF within 90 days was 3.2% following myocardial infarction, 2.8% in ischemic cardiomyopathy and 2.5% in nonischemic cardiomyopathy.  

“Publication of the ACE-PAS results marks an important milestone in advancing the evidence base for wearable defibrillator therapy and monitoring,” said Brian Webster, President and CEO of Kestra Medical Technologies. “Real-world evidence at this scale reinforces confidence in the ASSURE system and strengthens the clinical foundation for protecting patients during recovery. We will continue to build on these insights to give providers more ways to protect at risk patients.”

Drawing on ACE-PAS data, Kestra introduced an enhanced detection algorithm in April 2026 for the ASSURE WCD that further reduces the already low false-positive alarm burden while maintaining VT/VF detection sensitivity. With the enhanced algorithm, the inappropriate shock rate is projected to decrease by nearly 70%, from 0.0065 to 0.0020 per patient-month.1, 2

The peer-reviewed publication, “Real-World Performance of a Novel Wearable Cardioverter-Defibrillator System: Primary Results From a National Prospective Post-Approval Registry Study (ACE-PAS),” is available at http://doi.org/10.1111/jce.70556

About ACE-PAS
The ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) was an FDA-mandated, prospective, single-arm post-approval registry evaluating the safety and effectiveness of the ASSURE Wearable Cardioverter Defibrillator in routine clinical use. Funded by Kestra, the study included 21,612 patients fitted between November 2021 and July 2025. Primary endpoints were all-shock VT/VF conversion success and inappropriate-shock incidence, evaluated against prespecified performance goals.

About Kestra 
Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. 

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. For a discussion of factors that could cause actual results to differ, see Kestra's filings with the U.S. Securities and Exchange Commission. Kestra undertakes no obligation to update any forward-looking statements except as required by law.

  1. Finch D, et al. Research Square. April 22, 2026. Preprint.
  2. Poole JE, et al. Circulation. 2025;152:e526–e605.


Media contact 
Rhiannon Pickus 
rhiannon.pickus@kestramedical.com 

Investor contact 
Neil Bhalodkar 
neil.bhalodkar@kestramedical.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kestra's ACE-PAS study show about ASSURE defibrillator effectiveness and safety?

ASSURE met both primary safety and effectiveness endpoints in ACE-PAS. It converted all 303 analyzable ventricular tachycardia or ventricular fibrillation shock events with one or more shocks. The inappropriate-shock rate was 0.0065 per patient-month, outperforming the prespecified safety performance goal.

How long did arrhythmia risk persist in Kestra's ACE-PAS study?

VT/VF events continued beyond the first month, although 55% of episodes occurred during that month. Overall, 2.6% of patients experienced at least one shocked or unshocked VT/VF event.

Keep reading